The expected signs and symptoms with overdosage of albuterol are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation (e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis).Label In particular, the signs of salbutamol overdosage are significant tachycardia and/or significant muscle tremor.F3265,F3268
Hypokalaemia may occur following overdosage with salbutamol.F3265 Serum potassium levels should be monitored.F3265
Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose.F3265,F3268
Salbutamol is categorized as Pregnancy Category C.Label There are no adequate and well-controlled trials with salbutamolc or albuterol sulfate in pregnant women.Label During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with salbutamol.Label Some of the mothers were taking multiple medications during their pregnancies.Label No consistent pattern of defects can be discerned, and a relationship between salbutamol use and congenital anomalies has not been established.Label Animal reproduction studies in mice and rabbits revealed evidence of teratogenicity.Label Salbutamol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetusLabel]. Women should be advised to contact their physicians if they become pregnant while taking salbutamol.Label
Since there exists a potential for beta-agonist interference with uterine contractility, the use of salbutamol during labour should be restricted to those patients in whom the benefits clearly outweigh the risk.Label
Plasma levels of albuterol sulfate and HFA-134a after inhaled therapeutic doses are very low in humans, but it is not known whether the components of salbutamol are excreted in human milk.Label Because of the potential for tumorigenicity shown for albuterol in animal studies and lack of experience with the use of salbutamol by nursing mothers, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.Label Caution should be exercised when salbutamol is administered to a nursing woman.Label
The safety and effectiveness of salbutamol in children younger than 4 years of age has not yet been established.Label
Clinical trials of VENTOLIN HFA did not include sufficient numbers of subjects aged 65 years and older to determine whether older subjects respond differently than younger subjects.Label Other reported clinical experience has not identified differences in responses between the elderly and younger patients.Label In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.Label
The LD50 value was determined to be 1100 mg/kg (orally in mice).
Salbutamol (Albuterol USAN) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.Label,A174379,A174400
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Loxapine | The therapeutic efficacy of Salbutamol can be decreased when used in combination with Loxapine. |
| Valsartan | Salbutamol may decrease the antihypertensive activities of Valsartan. |
| Ramipril | Salbutamol may decrease the antihypertensive activities of Ramipril. |
| Remikiren | Salbutamol may decrease the antihypertensive activities of Remikiren. |
| Olmesartan | Salbutamol may decrease the antihypertensive activities of Olmesartan. |
| Minoxidil | Salbutamol may decrease the antihypertensive activities of Minoxidil. |
| Trandolapril | Salbutamol may decrease the antihypertensive activities of Trandolapril. |
| Benazepril | Salbutamol may decrease the antihypertensive activities of Benazepril. |
| Candoxatril | Salbutamol may decrease the antihypertensive activities of Candoxatril. |
| Nitroglycerin | Salbutamol may decrease the antihypertensive activities of Nitroglycerin. |
| Metyrosine | Salbutamol may decrease the antihypertensive activities of Metyrosine. |
| Cryptenamine | Salbutamol may decrease the antihypertensive activities of Cryptenamine. |
| Candesartan cilexetil | Salbutamol may decrease the antihypertensive activities of Candesartan cilexetil. |
| Eprosartan | Salbutamol may decrease the antihypertensive activities of Eprosartan. |
| Quinapril | Salbutamol may decrease the antihypertensive activities of Quinapril. |
| Telmisartan | Salbutamol may decrease the antihypertensive activities of Telmisartan. |
| Irbesartan | Salbutamol may decrease the antihypertensive activities of Irbesartan. |
| Deserpidine | Salbutamol may decrease the antihypertensive activities of Deserpidine. |
| Pentolinium | Salbutamol may decrease the antihypertensive activities of Pentolinium. |
| Trimethaphan | Salbutamol may decrease the antihypertensive activities of Trimethaphan. |
| Captopril | Salbutamol may decrease the antihypertensive activities of Captopril. |
| Cilazapril | Salbutamol may decrease the antihypertensive activities of Cilazapril. |
| Saprisartan | Salbutamol may decrease the antihypertensive activities of Saprisartan. |
| Spirapril | Salbutamol may decrease the antihypertensive activities of Spirapril. |
| Debrisoquine | Salbutamol may decrease the antihypertensive activities of Debrisoquine. |
| Sitaxentan | Salbutamol may decrease the antihypertensive activities of Sitaxentan. |
| Diethylnorspermine | Salbutamol may decrease the antihypertensive activities of Diethylnorspermine. |
| Temocapril | Salbutamol may decrease the antihypertensive activities of Temocapril. |
| Hexamethonium | Salbutamol may decrease the antihypertensive activities of Hexamethonium. |
| Rauwolfia serpentina root | Salbutamol may decrease the antihypertensive activities of Rauwolfia serpentina root. |
| Angiotensin 1-7 | Salbutamol may decrease the antihypertensive activities of Angiotensin 1-7. |
| Imidapril | Salbutamol may decrease the antihypertensive activities of Imidapril. |
| BQ-123 | Salbutamol may decrease the antihypertensive activities of BQ-123. |
| Dihydralazine | Salbutamol may decrease the antihypertensive activities of Dihydralazine. |
| Zofenopril | Salbutamol may decrease the antihypertensive activities of Zofenopril. |
| Guanoxan | Salbutamol may decrease the antihypertensive activities of Guanoxan. |
| Delapril | Salbutamol may decrease the antihypertensive activities of Delapril. |
| Vincamine | Salbutamol may decrease the antihypertensive activities of Vincamine. |
| Linsidomine | Salbutamol may decrease the antihypertensive activities of Linsidomine. |
| Guanoxabenz | Salbutamol may decrease the antihypertensive activities of Guanoxabenz. |
| Tolonidine | Salbutamol may decrease the antihypertensive activities of Tolonidine. |
| Endralazine | Salbutamol may decrease the antihypertensive activities of Endralazine. |
| Cadralazine | Salbutamol may decrease the antihypertensive activities of Cadralazine. |
| Bietaserpine | Salbutamol may decrease the antihypertensive activities of Bietaserpine. |
| Guanazodine | Salbutamol may decrease the antihypertensive activities of Guanazodine. |
| Methoserpidine | Salbutamol may decrease the antihypertensive activities of Methoserpidine. |
| Guanoclor | Salbutamol may decrease the antihypertensive activities of Guanoclor. |
| Candesartan | Salbutamol may decrease the antihypertensive activities of Candesartan. |
| Tocopherylquinone | Salbutamol may decrease the antihypertensive activities of Tocopherylquinone. |
| Benazeprilat | Salbutamol may decrease the antihypertensive activities of Benazeprilat. |
| Fosinoprilat | Salbutamol may decrease the antihypertensive activities of Fosinoprilat. |
| Ramiprilat | Salbutamol may decrease the antihypertensive activities of Ramiprilat. |
| Perindoprilat | Salbutamol may decrease the antihypertensive activities of Perindoprilat. |
| Quinaprilat | Salbutamol may decrease the antihypertensive activities of Quinaprilat. |
| Enalapril | Salbutamol may decrease the antihypertensive activities of Enalapril. |
| Lercanidipine | Salbutamol may decrease the antihypertensive activities of Lercanidipine. |
| Bosentan | Salbutamol may decrease the antihypertensive activities of Bosentan. |
| Clonidine | Salbutamol may decrease the antihypertensive activities of Clonidine. |
| Ambrisentan | Salbutamol may decrease the antihypertensive activities of Ambrisentan. |
| Pinacidil | Salbutamol may decrease the antihypertensive activities of Pinacidil. |
| Riociguat | Salbutamol may decrease the antihypertensive activities of Riociguat. |
| Aliskiren | Salbutamol may decrease the antihypertensive activities of Aliskiren. |
| Manidipine | Salbutamol may decrease the antihypertensive activities of Manidipine. |
| Selexipag | Salbutamol may decrease the antihypertensive activities of Selexipag. |
| Naftopidil | Salbutamol may decrease the antihypertensive activities of Naftopidil. |
| Dexniguldipine | Salbutamol may decrease the antihypertensive activities of Dexniguldipine. |
| Amlodipine | Salbutamol may decrease the antihypertensive activities of Amlodipine. |
| Levamlodipine | Salbutamol may decrease the antihypertensive activities of Levamlodipine. |
| Azilsartan medoxomil | Salbutamol may decrease the antihypertensive activities of Azilsartan medoxomil. |
| Diazoxide | Salbutamol may decrease the antihypertensive activities of Diazoxide. |
| Midodrine | The risk or severity of hypertension can be increased when Midodrine is combined with Salbutamol. |
| Bethanidine | Salbutamol may decrease the antihypertensive activities of Bethanidine. |
| Zolmitriptan | The risk or severity of hypertension can be increased when Zolmitriptan is combined with Salbutamol. |
| Phenylephrine | The risk or severity of hypertension can be increased when Phenylephrine is combined with Salbutamol. |
| Doxapram | The risk or severity of hypertension can be increased when Doxapram is combined with Salbutamol. |
| Metaraminol | The risk or severity of hypertension can be increased when Metaraminol is combined with Salbutamol. |
| Guanabenz | Salbutamol may decrease the antihypertensive activities of Guanabenz. |
| Methoxamine | The risk or severity of hypertension can be increased when Methoxamine is combined with Salbutamol. |
| Phenmetrazine | The risk or severity of hypertension can be increased when Phenmetrazine is combined with Salbutamol. |
| Pseudoephedrine | The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Salbutamol. |
| Omapatrilat | Salbutamol may decrease the antihypertensive activities of Omapatrilat. |
| Remifentanil | The risk or severity of hypertension can be increased when Remifentanil is combined with Salbutamol. |
| Oxymetazoline | The risk or severity of hypertension can be increased when Oxymetazoline is combined with Salbutamol. |
| Diethylpropion | The risk or severity of hypertension can be increased when Diethylpropion is combined with Salbutamol. |
| Naratriptan | The risk or severity of hypertension can be increased when Naratriptan is combined with Salbutamol. |
| Frovatriptan | The risk or severity of hypertension can be increased when Frovatriptan is combined with Salbutamol. |
| Rescinnamine | Salbutamol may decrease the antihypertensive activities of Rescinnamine. |
| Lisdexamfetamine | The risk or severity of hypertension can be increased when Salbutamol is combined with Lisdexamfetamine. |
| Ephedrine | The risk or severity of hypertension can be increased when Salbutamol is combined with Ephedrine. |
| Mephentermine | The risk or severity of hypertension can be increased when Salbutamol is combined with Mephentermine. |
| MMDA | The risk or severity of hypertension can be increased when Salbutamol is combined with MMDA. |
| Midomafetamine | The risk or severity of hypertension can be increased when Salbutamol is combined with Midomafetamine. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of hypertension can be increased when Salbutamol is combined with 2,5-Dimethoxy-4-ethylamphetamine. |
| 4-Methoxyamphetamine | The risk or severity of hypertension can be increased when Salbutamol is combined with 4-Methoxyamphetamine. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of hypertension can be increased when Salbutamol is combined with 4-Bromo-2,5-dimethoxyamphetamine. |
| Tenamfetamine | The risk or severity of hypertension can be increased when Salbutamol is combined with Tenamfetamine. |
| Chlorphentermine | The risk or severity of hypertension can be increased when Salbutamol is combined with Chlorphentermine. |
| Dextroamphetamine | The risk or severity of hypertension can be increased when Salbutamol is combined with Dextroamphetamine. |
| Phendimetrazine | The risk or severity of hypertension can be increased when Salbutamol is combined with Phendimetrazine. |
| Epicaptopril | The risk or severity of hypertension can be increased when Salbutamol is combined with Epicaptopril. |